Daily Cosmetic Research Analysis
Analyzed 23 papers and selected 3 impactful papers.
Summary
Three papers stood out today: a multi-fluid proteomics and cohort-validation study identifying plasma neurofilament light chain (NFL) as a pan-stage biomarker for diabetic retinopathy; a mechanistic skin carcinogenesis study showing UVA attenuates UVB-induced damage via the c-Fos/XRCC4 axis; and a human in vivo study demonstrating ultra-long-chain ceramides deliver superior skin barrier restoration. Together, they advance biomarker-driven care, photobiology of cancer risk, and evidence-based cosmeceutical formulation.
Research Themes
- Biomarker discovery and validation in ophthalmology
- Photobiology mechanisms in skin carcinogenesis
- Evidence-based formulation for skin barrier repair
Selected Articles
1. Integrated intraocular-plasma proteomics reveals conserved biomarkers for diabetic retinopathy progression: a multi-fluid biopsy study.
High-throughput intraocular proteomics and cross-cohort validation identified 25 conserved markers of diabetic retinopathy progression, with plasma neurofilament light chain (NFL) emerging as a robust, minimally invasive biomarker. Plasma NFL distinguished prevalent DR and predicted incident DR and vascular events over 12 years, improving risk reclassification beyond conventional factors.
Impact: This study integrates discovery proteomics with prospective validation to deliver a pan-stage, blood-based biomarker for diabetic retinopathy that also stratifies systemic vascular risk.
Clinical Implications: Plasma NFL could be incorporated into risk stratification and screening pathways to identify patients at heightened risk for DR progression and vascular complications, informing follow-up intensity and preventive strategies.
Key Findings
- Temporal intraocular proteomics identified 40 candidates; 25 showed conserved directional changes across datasets (p<0.05).
- Single-cell mapping localized 15 markers, including NFL, to retinal neurons/glia.
- Plasma NFL associated with prevalent DR (OR 1.98), incident DR (HR 2.01), and micro/macrovascular events (HR 2.28/1.49) over 12 years.
- NFL improved predictive performance beyond conventional risk factors (NRI 0.194; IDI 0.015).
Methodological Strengths
- Multi-fluid discovery with independent cross-cohort validation and single-cell localization
- Prospective risk modeling in a large biobank with long follow-up
Limitations
- Observational design susceptible to residual confounding
- Proteomic platform and thresholds may affect generalizability and clinical translation
Future Directions: Validate NFL in diverse populations with standardized assays; test integration into screening algorithms and evaluate impact on clinical outcomes.
AIMS/HYPOTHESIS: The aim of this study was to identify conserved biomarkers for diabetic retinopathy progression, addressing the lack of minimally invasive biomarkers to track the entire continuum of diabetic retinopathy. METHODS: We conducted high-throughput proteomics (SomaScan v4.1) on aqueous humour from the Guangdong DR Multiple-Omics Study (n=32). Temporal protein clusters were identified using soft clustering of temporal trajectories. Candidates were validated in a US dataset and localised via single-cell RNA-seq in an oxygen-induced retinopathy mouse model. The clinical relevance of plasma-detectable markers was assessed cross-sectionally and prospectively in individuals with diabetes from the UK Biobank (n=2495). RESULTS: In the discovery dataset (mean age 68.5±9.0 years; 56.3% men, 43.8% women), temporal proteomic profiling identified 40 candidate biomarkers whose concentration showed monotonic changes during diabetic retinopathy progression. Of these, 25 showed conserved directional patterns in the validation dataset (17 increasing and eight decreasing, all p<0.05). Single-cell mapping further localised 15 candidates, including neurofilament light chain (NFL), to retinal neurons and glia. In the UK Biobank individuals, baseline plasma NFL distinguished those with diabetic retinopathy from control individuals (OR 1.98 [95% CI 1.61, 2.42]) and predicted incident diabetic retinopathy (HR 2.01 [95% CI 1.48, 2.73]) and vascular complications (microvascular, HR 2.28 [95% CI 1.94, 2.69]; macrovascular, HR 1.49 [95% CI 1.26, 1.77]) over a median follow-up of 12 years. Plasma NFL enhanced the predictability of a conventional risk factor model for diabetic retinopathy (net reclassification improvement [NRI] 0.194 [95% CI 0.042, 0.297]; integrated discrimination improvement [IDI] 0.015 [95% CI 0.003, 0.047]) and enabled risk stratification of vascular complications. CONCLUSIONS/INTERPRETATION: NFL represents a pan-stage biomarker for diabetic retinopathy progression, detectable through minimally invasive plasma testing, and is associated with risks of diabetic vascular complications.
2. Ultraviolet A Plays a Protective Role in Ultraviolet B-induced Squamous Cell Carcinoma through c-Fos/XRCC4 Axis.
UVA pre-exposure attenuated UVB-induced DNA damage and keratinocyte transformation via modulation of the c-Fos/XRCC4 axis. XRCC4 upregulation mediated protection, while c-Fos suppressed XRCC4 transcription; a c-Fos C154S mutant enhanced suppression and transformation.
Impact: Reveals a mechanistic pathway linking UVA exposure to reduced UVB carcinogenicity via DNA repair regulation, challenging simplistic views that all solar UVA is uniformly harmful.
Clinical Implications: Findings suggest opportunities for chemopreventive strategies that modulate the c-Fos/XRCC4 axis and for photoprotection designs considering wavelength interactions, while reinforcing that overall photoprotection remains essential.
Key Findings
- UVA reduced UVB-induced DNA damage and keratinocyte transformation in cSCC models.
- XRCC4 mRNA was significantly increased with UVA/UVB versus UVB alone; XRCC4 knockdown attenuated UVA's protective effect.
- UVA pre-treatment blunted UVB responsiveness of AP-1; c-Fos repressed XRCC4 transcription, and the c-Fos C154S mutant enhanced repression and transformation.
Methodological Strengths
- Convergent mechanistic approaches: DNA repair arrays, gene knockdown, and luciferase reporter assays
- Functional mutant analysis linking c-Fos activity to keratinocyte transformation
Limitations
- Translational extrapolation to human sun exposure regimens and doses requires caution
- Extent of in vivo validation and dose-response characterization is limited in the abstract
Future Directions: Define dose-response and timing windows for UVA-mediated protection in vivo; test c-Fos/XRCC4-targeted chemopreventive agents and assess relevance in human skin models.
For decades, there has been a strong epidemiological association between solar ultraviolet (UV) radiation and skin cancer. UVB and UVA are the major UV bands that can penetrate the atmosphere, playing vital roles in skin carcinogenesis. Our research group previously discovered that a specific dose of UVA can inhibit the increase of AP1 activity caused by UVB. It is unclear whether UVA plays a particular role in UVB-induced skin cancer. Here, we report that UVA was protective in UVB-induced cSCC by attenuating UVB-induced DNA damage. DNA repair chip array results showed that the mRNA level of XRCC4 significantly increased in the UVA/B group compared with the UVB group, and knockdown of XRCC4 partly blocked the protective effect of UVA in UVB-induced DNA damage. The activator protein 1 (AP-1), the predicted transcriptional regulatory factor of XRCC4, exhibited no sensitivity to UVB radiation upon pre-treatment with UVA. More importantly, the luciferase reporter assay showed that c-Fos, which is the critical component of AP-1, inhibited the transcription of XRCC4, and mutation of c-Fos (cys154 > serine) partly enhanced this effect and promoted keratinocyte transformation. UVA was protective in UVB-induced cSCC by interacting with the c-Fos/XRCC4 axis.
3. Impact of Ceramide Acyl Chain Length on Human Skin Barrier Recovery and Hydration.
In a vehicle-controlled, intra-subject human study coupled with LC-MS/MS lipidomics, ultra-long-chain (C24–C30) ceramide formulations significantly increased C24/C26 ceramides and outperformed shorter-chain ceramides in restoring barrier function, hydration, and stratum corneum cohesion.
Impact: Provides the first in vivo human evidence that ceramide acyl chain length is a critical determinant of barrier repair efficacy, guiding rational design of cosmeceuticals and therapeutic moisturizers.
Clinical Implications: Formulators and clinicians should prioritize ultra-long-chain ceramides when selecting or prescribing barrier-repair products, particularly for conditions with impaired barrier function such as atopic dermatitis.
Key Findings
- C24–C30 ceramide formulations significantly increased C24 and C26 ceramides in human stratum corneum.
- Ultra-long-chain ceramides enhanced barrier recovery, hydration, and SC cohesion vs. C18 ceramides.
- C16–C24 formulations primarily improved hydration with less impact on barrier recovery.
Methodological Strengths
- Vehicle-controlled, intra-subject human design reducing inter-individual variability
- LC-MS/MS ceramide profiling corroborating functional outcomes
Limitations
- Sample size and duration not specified; long-term durability unknown
- Generalizability across skin types and disease states requires further study
Future Directions: Randomized, longer-term trials in healthy and diseased skin to define optimal chain-length ratios and clinical endpoints.
OBJECTIVE: To compare the effects of ceramide acyl chain length on human skin barrier function. METHODS: Mixtures of phytoceramide containing non-hydroxy fatty acids (CER NPs) with different acyl chain lengths and corresponding test creams were prepared: C16-C24 CER NP and C24-C30 CER NP (ultra-long-chain, ULC CER NP). The content of C24 CER NP in these formulations was 0.3% and 39%, respectively. Liquid chromatography-tandem mass spectrometric (LC-MS/MS) analysis of skin ceramides was performed using tape-stripped human stratum corneum (SC) samples. A vehicle-controlled intra-subject human study was conducted to assess acute skin barrier recovery, skin hydration, and SC cohesion. RESULTS: Levels of C24 and C26 ceramides were significantly increased in skin treated with C24-C30 CER NP. These analytical results were consistent with the findings from the human efficacy study. Functional evaluations demonstrated that C24-C30 CER NP significantly enhanced barrier recovery, skin hydration, and SC cohesion compared with C18 CER NP, whereas the C16-C24 CER NP formulation primarily improved skin hydration. Overall, the C24-C30 CER NP formulation exhibited the strongest barrier-enhancing effects among the tested formulations. CONCLUSION: This study provides the first in vivo human evidence that ceramides with longer acyl chains confer superior improvements in skin barrier function compared with shorter-chain ceramides. These findings highlight the critical role of acyl chain length in ceramide-mediated barrier enhancement and support the rational design of ceramide-based formulations for optimized skin barrier restoration.